What is the recommended dosing and administration protocol for Vyepti (eptinezumab) in adult patients for preventive migraine treatment, including initial dose, possible escalation to 300 mg, infusion duration, monitoring, and contraindications?

Vyepti (Eptinezumab) Dosing and Administration

The recommended dose is 100 mg administered by intravenous infusion every 3 months, with escalation to 300 mg every 3 months for patients who may benefit from higher dosing. 1

Standard Dosing Protocol

• Initial dose: 100 mg IV infusion every 12 weeks (3 months) 1
• Escalation option: 300 mg IV infusion every 12 weeks for patients requiring enhanced efficacy 1
• Both doses demonstrate sustained efficacy, with the 300 mg dose showing particularly robust reductions in monthly migraine days (4.3–5.3 fewer days vs. 3.2–4.0 with placebo across treatment intervals) 2

Preparation and Dilution

• Dilution requirement: Must be diluted in exactly 100 mL of 0.9% Sodium Chloride Injection, USP before administration 1
• For 100 mg dose: Withdraw 1 mL from a single-dose vial and inject into 100 mL saline bag 1
• For 300 mg dose: Withdraw 1 mL from each of 3 single-dose vials (total 3 mL) and inject into 100 mL saline bag 1
• Infusion bag materials: Must be polyvinyl chloride (PVC), polyethylene (PE), or polyolefin (PO) 1
• Storage after dilution: Must infuse within 8 hours at room temperature (20°C–25°C); do not freeze 1
• Gently invert to mix; do not shake 1

Infusion Administration

• Infusion duration: Approximately 30 minutes 1
• Route: Intravenous infusion only—never administer as IV push or bolus 1
• Filter requirement: Use 0.2 or 0.22 micron in-line or add-on sterile filter 1
• Line flushing: After infusion completion, flush line with 20 mL of 0.9% Sodium Chloride Injection 1
• No other medications should be mixed with or administered through the same infusion set 1

Monitoring Requirements

• Pre-infusion inspection: Visually inspect for particulate matter and discoloration; do not use if cloudy, discolored, or contains visible particles 1
• Hypersensitivity monitoring: Observe during and after infusion for signs of hypersensitivity reactions (angioedema, urticaria, facial flushing, dyspnea, rash) 1
• Most hypersensitivity reactions occur during infusion and may require discontinuation or treatment 1
• Efficacy assessment: Evaluate therapeutic benefit only after 3–6 months of treatment, as earlier assessment may underestimate full effect 3

Contraindications

• Absolute contraindication: Serious hypersensitivity to eptinezumab-jjmr or any excipients, including prior anaphylaxis or angioedema 1

Position in Treatment Algorithm

• Guideline positioning: Eptinezumab receives a "weak for" recommendation from the 2023 VA/DoD guidelines for both episodic and chronic migraine prevention 4
• Treatment hierarchy: The American College of Physicians positions CGRP monoclonal antibodies as second-line therapy after failure of conventional preventives (beta-blockers, valproate, venlafaxine, amitriptyline), driven primarily by cost considerations 3
• Alternative CGRP-mAbs: Consider erenumab, fremanezumab, or galcanezumab before eptinezumab, as these have stronger guideline recommendations 4
• The primary disadvantage of eptinezumab is the requirement for healthcare center infrastructure and IV administration, creating additional burden and cost compared to subcutaneous CGRP-mAbs 4

Efficacy Timeline and Duration

• Onset of benefit: Reductions in migraine frequency begin as early as day 1 after initial infusion 2, 5
• Sustained effect: Efficacy is maintained throughout 1–2 years of continued treatment 2, 6
• Treatment pause consideration: After 6–12 months of successful therapy, consider pausing to determine if preventive treatment can be discontinued 3

Safety Profile

• Most common adverse events (≥2%): Nasopharyngitis and hypersensitivity reactions 1
• Other frequent events include upper respiratory tract infection, sinusitis, influenza, bronchitis, and fatigue 7, 6
• Treatment-emergent adverse events are generally mild and occur at similar rates to placebo 7, 5
• Discontinuation rate: 6.3% discontinued due to adverse events in long-term studies, including 3 patients with infusion-related hypersensitivity 6
• Immunogenicity: Anti-eptinezumab antibodies peak at week 24 but decline to undetectable levels with continued dosing and do not impact safety profile 7, 6

Critical Pitfalls to Avoid

• Do not assess efficacy before 3 months: Premature discontinuation may occur if benefit is evaluated too early 3
• Do not use as first-line therapy: Unless conventional preventives are contraindicated, cost-effectiveness principles mandate trying beta-blockers, antidepressants, or antiseizure medications first 3
• Do not administer as IV push: Only infuse over 30 minutes to minimize hypersensitivity risk 1
• Do not mix with other medications: Use dedicated IV line and flush appropriately 1